ArticleTherapeutic delivery2025
Evaluating the potential of travoprost-thymoquinone co-loaded liposomes: a glaucomatous rabbit model study.
Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimGlaucoma is associated with abnormal IOP elevation leading to irreversible blindness. In this study, we explore the therapeutic potential of thymoquinone in combination with travoprost to enhance the treatment efficacy of glaucoma.
methodThymoquinone-travoprost co-loaded liposomes (LP-TP-TQ) were formulated using thin-film hydration technique and optimized using BBD. Optimized liposomes underwent comprehensive ex vivo, in vitro, and preclinical characterization.
resultsThe optimized formulation demonstrated a vesicle size of 96.02 ± 1.35 nm having negative surface charge encapsulated 81.55 ± 1.12% of TQ and 86.88 ± 0.55% of TP. LP-TP-TQ released drug sustained for 24 hr, while ex vivo permeation studies confirmed enhanced ocular penetration. In human corneal epithelial cells, LP-TP-TQ exhibited superior viability and internalization properties. The IOP-lowering efficacy was evaluated in an in vivo glaucomatous rabbit model, where significant reductions in IOP were observed, underscoring the potential of co-delivering TQ and TP via liposomes to ameliorate glaucomatous damage. Results suggest that LP-TP-TQ presents a promising strategy for advancing glaucoma management, laying the groundwork for future clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.